Status:
RECRUITING
The Use of Butyrate Therapy in Pediatric Ulcerative Colitis
Lead Sponsor:
Children's Hospital Los Angeles
Conditions:
Ulcerative Colitis
Eligibility:
All Genders
7-21 years
Phase:
PHASE1
Brief Summary
Butyrate is an important metabolite produced by the gut microbiome and has been shown as a helpful therapy in ulcerative colitis. This is a feasibility study to determine the efficacy of butryate enem...
Detailed Description
butyrate enemas will be administered for 12 weeks to children ages 7 to 21 with mild to moderate ulcerative colitis to determine if butyrate therapy can help improve the clinical disease in those chil...
Eligibility Criteria
Inclusion
- 7-21 years, mild to moderate ulcerative colitis
Exclusion
- UC therapy within 4 weeks of study medication initiation
- infectious colitis, -pregnancy
Key Trial Info
Start Date :
June 29 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2027
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT05218850
Start Date
June 29 2022
End Date
June 30 2027
Last Update
April 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital Los Angeles
Los Angeles, California, United States, 90027